rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EVO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Evotec SE (EVOTF) (Q3 2026) Earnings Call Highlights: Near-Breakeven EBITDA, Horizon Savings ...
      Nov 6Yahoo FinanceEVO
      What Evotec (EVO) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceEVO
      Evotec SE ADR earnings beat by $0.09, revenue topped estimates
      Nov 5Investing.comEVO
      Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

      Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.

      Oct 29Yahoo FinanceEVO
      Did Evotec’s 60% Drop Catch You Out? What Investors Missed
      Oct 25Yahoo FinanceEVO
      Why is Evotec stock advancing today?
      Oct 14Investing.comEVO
      Evotec shares jump after preliminary 9-month revenue, EBITDA top estimates
      Oct 14Investing.comEVO
      Evotec Announces Chief Scientific Officer Transition
      Sep 28Yahoo FinanceEVO
      Evotec: The Market Seems Split On The Company's Prospects (NASDAQ:EVO)

      Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. Read why EVO stock is a Buy.

      Sep 21Seeking AlphaEVO
      Investment Update: Evotec (NASDAQ:EVO)

      Investment Update: Long article based on a reader request.

      Sep 19Seeking AlphaEVO
      Evotec at Morgan Stanley healthcare conference: push to clarify its story
      Sep 16Investing.comEVOMS
      Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
      Sep 9Yahoo FinanceEVO
      Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors
      Sep 2Yahoo FinanceEVO
      Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

      Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.

      Sep 2Yahoo FinanceEVO

      This is the newest page. Registered accounts read further back.